Insight

Sep 1, 2024, 08:23

Maria Carmen De Santis: Significance of HER2-Low in DCIS of the breast

Maria Carmen De Santis, Radiation Oncologist at National Cancer Institute, Milan, shared on X:

“Significance of HER2-Low in DCIS How might it impact on clinical practice in the foreseeable future?

Knowledge that DCIS with low HER2 expression is associated with less aggressive features could inform less aggressive future therapeutic interventions.”

Source: Maria Carmen De Santis/X

Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast.

Authors: Chiara M. Ciniselli, Paolo Verderio, Paolo Baili, Milena Sant, Sara Pizzamiglio, Valeria Duroni, Filippo G. de Braud, Secondo Folli, Gianfranco Scaperrotta, Maria C. De Santis, Giovanni Apolone, Cinzia De Marco, Andrea Vingiani, Vera Cappelletti, Giancarlo Pruneri, and Serena Di Cosimo.

Maria

Andrea Vingiani cancer Chiara M. Ciniselli Cinzia De Marco DCIS Filippo G. de Braud Giancarlo Pruneri Gianfranco Scaperrotta Giovanni Apolone HER2 expression Maria C. De Santis Maria Carmen De Santis Milena Sant National Cancer Institute NCI OncoDaily Oncology Paolo Baili Paolo Verderio Sara Pizzamiglio Secondo Folli Serena Di Cosimo Valeria Duroni Vera Cappelletti

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage